Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer

Breast Cancer Research and Treatment

Volumn 145, Issue 2, 2014, Pages 317-330

  Jerjees, Dena A ^a,b   Alabdullah, M ^c   Green, Andrew R ^a   Alshareeda, Alaa ^a   Macmillan, R D ^d   Ellis, Ian O ^a   Rakha, Emad A ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF MOSUL   (Iraq)

^c Department of Surgery School of Medicine   (Iraq)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Breast carcinoma; HER2; Immunohistochemistry; KI67; Molecular classes

Indexed keywords

ANDROGEN RECEPTOR; ANGIOTENSIN 1 RECEPTOR; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CD71 ANTIGEN; CYTOKERATIN 18; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FRAGILE HISTIDINE TRIAD PROTEIN; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HISTONE H2AX; KI 67 ANTIGEN; MEMBRANE PROTEIN; METHYLTRANSFERASE; MUCIN 1; NERVE CELL ADHESION MOLECULE; PROTEIN BCL 2; PROTEIN CARM1; PROTEIN HER3; PROTEIN HER4; PROTEIN P53; PROTEIN PELP1; PROTEIN TFF1; PROTEIN TFF3; RAD51 PROTEIN; THYMIDINE KINASE 1; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; DNA REPAIR; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LUMINAL BREAST CANCER; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; AGED; BREAST TUMOR; CELL PROLIFERATION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL; UPREGULATION;

AGED; BREAST NEOPLASMS; CADHERINS; CELL PROLIFERATION; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84901696572     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2941-7     Document Type: Article

References (44)

1. Anderson E (2002) The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 4(5):197-201 (Pubitemid 34918998)
2. Clarke RB, Anderson E, Howell A (2004) Steroid receptors in human breast cancer. Trends Endocrinol Metab 15(7):316-323 (Pubitemid 39180006)
3. Mosselman S, Polman J, Dijkema R (1996) ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett 392(1):49-53 (Pubitemid 26268330)
4. Ctsu RI (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717 (Pubitemid 40719106)
5. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752
6. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869-10874 (Pubitemid 32878711)
7. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100(14):8418-8423 (Pubitemid 36842560)
8. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160-1167
9. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H (2007) FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin Cancer Res 13(15):4415-4421 (Pubitemid 47219708)
10. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F (2005) p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 447(4):688-694 (Pubitemid 41571183)
11. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492-2502 (Pubitemid 43854964)
12. Guiu S, Michiels S, Andre F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N et al (2012) Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 23(12):2997-3006
13. Hugh J, Hanson J, Cheang MCU, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27(8):1168-1176
14. Bhargava R, Dabbs D (2008) Luminal B breast tumors are not HER2 positive. Breast Cancer Res 10(5):404
15. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736-750
16. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, Wong J, Allred DC, Clark GM, Schiff R (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95(5):353-361 (Pubitemid 36395255)
17. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown R (2008) Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100(3):207-212 (Pubitemid 351480546)
18. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23(28):7212-7220
19. Liu S, Edgerton SM, Moore DH, Thor AD (2001) Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 7(6):1716-1723 (Pubitemid 32708640)
20. Spyratos F, Ferrero-Poüs M, Trassard M, Hacene K, Phillips E, Tubiana-Hulin M, Le Doussal V (2002) Correlation between MIB-1 and other proliferation markers. Cancer 94(8):2151-2159 (Pubitemid 34411971)
21. Brown RW, Allred C, Clark GM, Osborne CK, Hilsenbeck SG (1996) Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2(3):585-592 (Pubitemid 26099178)
22. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22(3):207-219
23. Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, Robertson JFR, Blamey R, Gee J, Nicholson RI et al (2008) Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 44(1):73-83 (Pubitemid 350256943)
24. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736-750
25. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7):2302-2310
26. Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO (2008) Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 39(6):857-865
27. Habashy HO, Rakha EA, Ellis IO, Powe DG (2013) The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer. Breast Cancer Res Treat 140(2):307-316
28. Alshareeda AT, Negm OH, Albarakati N, Green AR, Nolan C, Sultana R, Madhusudan S, Benhasouna A, Tighe P, Ellis IO et al (2013) Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer. Breast Cancer Res Treat 139(2):301-310
29. García-Caballero T, Grabau D, Green AR, Gregory J, Schad A, Kohlwes E, Ellis IO, Watts S, Mollerup J (2010) Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: A European multicentre study involving 168 specimens. Histopathology 56(4):472-480
30. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JFR, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340-350 (Pubitemid 40993329)
31. Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO (2006) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25-32
32. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Van De Rijn M, Jeffrey SS (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98(19):10869 (Pubitemid 32878711)
33. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci 100(14):8418 (Pubitemid 36842560)
34. Draghici S, Khatri P, Eklund AC, Szallasi Z (2006) Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 22(2):101-109 (Pubitemid 43152029)
35. Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM (2006) Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24(11):1656-1664 (Pubitemid 46622136)
36. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4):262-272 (Pubitemid 43264710)
37. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736-750
38. Aleskandarany MA, Green AR, Benhasouna AA, Barros FF, Neal K, Reis-Filho JS, Ellis IO, Rakha EA (2012) Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res 14(1):R3
39. Ihemelandu CU, Leffall LSD, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA (2007) Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol 14(10):2994-3003 (Pubitemid 47460642)
40. Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F, Kinoshita T, Takei H, Takahashi K, Ikeda M (2007) The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 16:72-77 (Pubitemid 350028561)
41. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7(1-2):4
42. Hu Z, Fan C, Oh D, Marron J, He X, Qaqish B, Livasy C, Carey L, Reynolds E, Dressler L (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genom 7(1):96 (Pubitemid 43786485)
43. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of american pathologists clinical practice guideline update. J Clin Oncol 31(31):3997-4013
44. Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA (2010) Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 28(11):1813-1820